Noxopharm Ltd (ASX:NOX) Insider Graham Kelly Purchases 65,553 Shares

Share on StockTwits

Noxopharm Ltd (ASX:NOX) insider Graham Kelly bought 65,553 shares of the business’s stock in a transaction that occurred on Wednesday, February 13th. The shares were acquired at an average price of A$0.42 ($0.30) per share, for a total transaction of A$27,270.05 ($19,340.46).

Graham Kelly also recently made the following trade(s):

  • On Friday, December 21st, Graham Kelly 62,500 shares of Noxopharm stock.

Shares of Noxopharm stock traded down A$0.02 ($0.01) on Friday, hitting A$0.41 ($0.29). The company had a trading volume of 25,000 shares. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 56.87. The stock has a market capitalization of $50.09 million and a P/E ratio of -4.51.

TRADEMARK VIOLATION WARNING: This story was posted by Fairfield Current and is owned by of Fairfield Current. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.fairfieldcurrent.com/news/2019/03/15/graham-kelly-purchases-65553-shares-of-noxopharm-ltd-nox-stock.html.

About Noxopharm

Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It is developing Veyonda, a dosage formulation of idronoxil, a generic anti-cancer agent for the treatment of late-stage cancers. The company also focuses on developing NYX-104, a drug intended to protect the brain from excitotoxicity; NYX-205, a drug to treat inflammation of the nervous tissue; and NYX-330, a PCSK9-inhibitor developed as a companion product for statin drugs in lowering low density lipoprotein cholesterol levels in patients at risk of cardiovascular disease.

Recommended Story: Cost of Capital Explained

Receive News & Ratings for Noxopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Noxopharm and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply